Published in BMC Immunol on July 18, 2005
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 4.69
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol (2006) 2.16
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med (2008) 1.91
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol (2007) 1.75
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol (2008) 1.71
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving. Proc Natl Acad Sci U S A (2012) 1.41
VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol (2006) 1.36
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med (2011) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Loss of T cell responses following long-term cryopreservation. J Immunol Methods (2007) 1.23
Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods (2010) 1.22
Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study. BMC Immunol (2006) 1.15
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines (2011) 1.04
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood (2012) 1.02
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine (2012) 0.96
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology (2008) 0.94
Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation. J Immunol Methods (2011) 0.94
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine (2008) 0.93
High dimensional flow cytometry for comprehensive leukocyte immunophenotyping (CLIP) in translational research. J Immunol Methods (2010) 0.92
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res (2011) 0.92
Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment. Clin Vaccine Immunol (2007) 0.91
Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking. PLoS One (2014) 0.88
Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot. Hum Vaccin Immunother (2014) 0.86
A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology (2008) 0.86
Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol (2013) 0.84
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int (2013) 0.80
Serial Measurements of Apoptotic Cell Numbers Provide Better Acceptance Criterion for PBMC Quality than a Single Measurement Prior to the T Cell Assay. Cells (2015) 0.79
Analyzing cellular immunity to AAV in a canine model using ELISPOT assay. Methods Mol Biol (2012) 0.76
Cytomegalovirus-Responsive CD8(+) T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease. Am J Transplant (2017) 0.76
Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn (2009) 0.75
Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial. J Biomed Biotechnol (2011) 0.75
Flow cytometric human leukocyte antigen-B27 typing with stored samples for batch testing. Ann Lab Med (2013) 0.75
Towards standardized automated immunomonitoring: an automated ELISpot assay for safe and parallelized functionality analysis of immune cells. Cytotechnology (2016) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods (2001) 4.25
Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest (1997) 4.01
On immunity against infections and vaccines: credo 2004. Scand J Immunol (2004) 3.29
Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods (1988) 2.84
Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol (1999) 2.79
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol (2003) 2.71
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
HIV vaccines 1983-2003. Nat Med (2003) 2.59
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol (2000) 2.51
Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol (1998) 2.48
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods (2003) 2.28
Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol (1999) 2.11
Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods (1998) 2.10
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med (1998) 1.99
Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods (2003) 1.99
CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods (2003) 1.98
The promise of cancer vaccines. Nat Rev Cancer (2004) 1.92
Malaria vaccine developments. Lancet (2004) 1.77
Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol (2001) 1.75
The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol (2001) 1.72
Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol (2003) 1.66
Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis (2002) 1.58
The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A (2000) 1.55
Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J Immunol Methods (2003) 1.47
Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. AIDS (2000) 1.45
Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol (2000) 1.45
Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res (2003) 1.43
Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol (2000) 1.43
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant (2002) 1.38
Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry. Blood (1999) 1.26
T-cell responses of vaccinated cancer patients. Curr Opin Immunol (2003) 1.18
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods (2001) 1.15
Effect of cryopreservation on measurement of cytomegalovirus-specific cellular immune responses in HIV-infected patients. J Acquir Immune Defic Syndr (2000) 1.08
Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol (2002) 1.07
Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients. J Immunol Methods (1997) 1.00
Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol (2001) 1.00
51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells. Natl Cancer Inst Monogr (1973) 0.99
CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods (2004) 0.98
Cryopreservation of human lymphocyte function as measured by in vitro assays. Int J Cancer (1976) 0.95
Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1-type dominant response. Int Immunol (2001) 0.93
Characterization of the role of mononuclear cell subpopulations in the in vitro lymphocyte proliferation assay. Clin Exp Immunol (1979) 0.87
Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr Drug Targets (2004) 0.84
T cell immunity to HIV: defining parameters of protection. Curr HIV Res (2003) 0.81
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Development and homeostasis of T cell memory in rhesus macaque. J Immunol (2002) 6.88
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol (2015) 2.80
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One (2012) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol (2006) 2.16
Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods (2005) 2.16
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther (2005) 1.87
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Use of tablet personal computers for sensitive patient-reported information. J Support Oncol (2009) 1.73
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med Care (2010) 1.67
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol (2003) 1.66
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res (2008) 1.65
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys (2008) 1.63
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. Nat Biotechnol (2004) 1.60
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res (2008) 1.59
The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry (2009) 1.58
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis (2002) 1.58
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
Standardization and optimization of multiparameter intracellular cytokine staining. Cytometry A (2008) 1.53
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 1.51
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
Screening for prostate cancer. CA Cancer J Clin (2009) 1.48
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood (2006) 1.46
Chilling outweighs photoperiod in preventing precocious spring development. Glob Chang Biol (2013) 1.43
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics (2013) 1.38
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol (2006) 1.36
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther (2009) 1.34
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol (2005) 1.34
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31